Advertisement
UK markets closed
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • CRUDE OIL

    83.10
    +1.75 (+2.15%)
     
  • GOLD FUTURES

    2,241.70
    +29.00 (+1.31%)
     
  • DOW

    39,868.59
    +108.51 (+0.27%)
     
  • Bitcoin GBP

    56,015.47
    +1,546.75 (+2.84%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    16,405.94
    +6.42 (+0.04%)
     
  • UK FTSE All Share

    4,338.05
    +12.12 (+0.28%)
     

Big Pharma's bet on Big Data creates opportunities and risks

* Novartis (LSE: 0QLR.L - news) plans to sell cloud-connected inhaler by 2019

* Part of companies' push into "Medical Internet of Things"

* Pharma and tech firms teaming up in hunt for Big Data

* But web-enabled devices present privacy and security risks

By John Miller

ZURICH, Jan 26 (Reuters) - Novartis wants every puff of its emphysema drug Onbrez to go into the cloud.

The Swiss drugmaker has teamed up with U.S (Other OTC: UBGXF - news) . technology firm Qualcomm (Hanover: QCI.HA - news) to develop an internet-connected inhaler that can send information about how often it is used to remote computer servers known as the cloud.

ADVERTISEMENT

This kind of new medical technology is designed to allow patients to keep track of their drug usage on their smartphones or tablets and for their doctors to instantly access the data over the web to monitor their condition.

It (Other OTC: ITGL - news) also creates a host of "Big Data" opportunities for the companies involved - with huge amounts of information about a medical condition and the efficacy of a drug or device being wirelessly transmitted to a database from potentially thousands, even millions, of patients.

The potential scale of the so-called "Medical Internet of Things" has not been lost on pharmaceutical and tech firms around the world, both big companies hunting growth and smaller ones looking to provide bespoke products and services.

It has created unlikely alliances.

Novartis' domestic rival Roche has also teamed up with Qualcomm and Danish diabetes drugmaker Novo Nordisk (Other OTC: NONOF - news) has partnered with IBM (NYSE: IBM - news) on cloud-linked device projects, for example, while healthcare device maker Medtronic (Berlin: 2M6.BE - news) is working with a U.S. data-analytics firm Glooko.

GlaxoSmithKline (Other OTC: GLAXF - news) , meanwhile, is in talks with Qualcomm about a medical technology joint venture potentially worth up to $1 billion, according to people familiar with the matter.

However, with the opportunity comes risk.

Security experts warn that hacked medical information can be worth more than credit card details on the black market as fraudsters can use it to fake IDs to buy medical equipment or drugs that can be resold, or file bogus insurance claims.

The U.S. Centers for Disease Control and Prevention estimates there are 35 million U.S. hospital discharges a year, a billion doctor and hospital visits and even more prescriptions, much of which is stored in cloud databases.

CLOUD CONCERN

Now (NYSE: DNOW - news) the "Medical Internet of Things" is introducing more and more web-connected devices into the equation and pushing even more confidential patient data on to the cloud.

This is creating potential new opportunities for thieves seeking to penetrate medical companies' security where they may target names, birth dates, policy numbers, billing data and the diagnosis codes needed to obtain drugs, say experts.

"The weakest link tends to be the medical device itself," said Rick Valencia, senior vice president of Qualcomm Life, Qualcomm's four-year-old healthcare unit. "They weren't designed with the idea in mind that they would be going over the network and the information would be residing in cloud infrastructure."

Medtronic (Xetra: 2M6.DE - news) , the world's largest standalone medical device maker, said in 2014 it lost patient records in separate cyberattacks at its diabetes business.

"The more information, the easier identity theft is and the more valuable the profiles that the hacker can sell to third parties," said Erik Vollebregt, a lawyer in Amsterdam who specialises in medical device cybersecurity and privacy.

He said it could also be possible for criminals to hack into web-connected medical devices, and threaten the lives of patients, to blackmail the manufacturer.

Despite no documented patient-endangering hacks, the U.S. Food and Drug Administration warned last year an infusion pump could be vulnerable to attack and asked healthcare providers to stop using it.

SMART LENS

Novartis aims to have its inhaler for chronic lung disease, to be on the market by 2019. Other pharma-tech alliances include Aerocrine (Other OTC: ACNOF - news) and Microsoft (NasdaqGS: MSFT - news) , which are working together on a cloud project to analyse data from allergy and asthma patients.

Google is, meanwhile, working with French drugmaker Sanofi (NasdaqGM: GCVRZ - news) to collect and analyse information from diabetes sufferers. The U.S. tech giant also has a partnership with Novartis to develop a smart contact lens that can monitor diabetics' glucose levels.

All the companies involved in such projects say they are going to extreme lengths to protect patients' data from hackers.

Philips (Amsterdam: PHIA.AS - news) has turned to San Francisco-based identity-management software maker ForgeRock to keep data from the Dutch company's medical devices from falling into the wrong hands.

Software (Amsterdam: SF6.AS - news) security expert Marie Moe, of Norway's SINTEF scientific research foundation, said the wireless ports in the pacemaker that keeps her heart beating left it vulnerable to intrusion - but that she could not survive without the device.

"Wireless interfaces are a great benefit to certain patient groups," she told Reuters. "But as a security researcher, I know connectivity also means vulnerability." (Additional reporting by Julie Steenhuysen in Chicago, Jim Finkle in Boston and Ben Hirschler in London; Editing by Pravin Char)